Clinical Trial Update: Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin [Phase 3]

View source ↗

Summary

A Phase III trial evaluating a fixed-dose combination of an SGLT2 inhibitor with a thiazolidinedione for type 2 diabetes patients on metformin has been withdraw…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SGLT2 inhibitor
• Thiazolidinedione (thiazolidinedione)

Snippet

Sponsor: Eurofarma Laboratorios S.A. | Conditions: Type 2 Diabetes Mellitus (T2DM) | Phase 3 | Status: WITHDRAWN